Abstracts tagged "Economics"

Abstract Number: 0059 • ACR Convergence 2022
Healthcare Resource Utilization and Costs of Management of Lupus Nephritis in Adult and Juvenile Patients with Systemic Lupus Erythematosus
Kenneth Kalunian¹, Janice Ma², Konrad Pisarczyk², Richard Leff³, Kiruthi Palaniswamy⁴ and Li Long⁴, ¹University of California San Diego, La Jolla, CA, ²Maple Health Group, LLC, New York, NY, ³Kezar Life Sciences, South San Francisco, CA, ⁴Kezar Life Sciences, Inc., South San Francisco, CA
Background/Purpose: Lupus nephritis (LN) is one of the most serious complications of systemic lupus erythematosus (SLE), which develops in about one-third of SLE patients within…
Abstract Number: 0067 • ACR Convergence 2022
Cost Per Responder in RA Patients Failing First Line Treatment
Manuel Cardozo, Pharmalab PHL, Huixquilucan, Mexico
Background/Purpose: The Colombian healthcare system is under economic pressure like many other systems in the world. In that sense, treatment choice involves cost in addition…
Abstract Number: 0283 • ACR Convergence 2022
The Association Between the Usage of Biological Disease Modified Anti Rheumatic Drug or JAK Inhibitor and the Burden of Treatment Costs on Daily Life (financial Toxicity) in RA Patients: A Cross-sectional Study Using the National Database of Rheumatic Diseases in Japan (NinJa)
Nobuyuki Yajima¹, Toshihiro Matsui² and Shigeto Tohma³, ¹Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, ²NHO Sagamihara National Hospital, Kanagawa, Japan, ³National Hospital Organization Tokyo National Hospital, Dallas, TX
Background/Purpose: Rheumatoid arthritis (RA) can be better controlled with the advent of biological disease modified anti rheumatic drug (bDMARDs) and JAK inhibitor (JAKi). However, these…
Abstract Number: 1286 • ACR Convergence 2022
Increasing Biosimilar Uptake in the Rheumatology Clinics Within a Large Academic Medical Center
Joad Eseddi¹, DeAnne Carmichael², Shannon Wishin³ and Puneet Bajaj², ¹UT Southwestern School of Medicine, Dallas, TX, ²UT Southwestern Medical Center, Dallas, TX, ³UT Southwestern Medical Centre, Dallas, TX
Background/Purpose: Biological drugs have revolutionized the treatment of rheumatic diseases. However, increasing the use of biologics over the past few years has directly contributed towards…
Abstract Number: 1312 • ACR Convergence 2022
Cost-Effectiveness of Sequential Treatment with Abaloparatide Followed by Alendronate in US Men at High Risk of Fracture
Mickael Hiligsmann¹, Stuart Silverman², Andrea J Singer³, Leny Pearman⁴, jake Mathew⁴, Yamei Wang⁴, John Caminis⁴ and Jean-Yves Reginster⁵, ¹Maastricht University, Maastricht, Netherlands, ²Cedar-Sinai Medical Center and UCLA School of Medicine, Los Angeles, CA, ³MedStar Georgetown University Hospital, Washington, DC, ⁴Radius Health, Inc., Waltham, MA, ⁵University of Liège, Liège, Belgium
Background/Purpose: Previous cost-effectiveness analyses in postmenopausal women (PmW) with osteoporosis (OP) demonstrated that sequential treatment with abaloparatide (ABL) followed by alendronate (ALN) resulted in lower…
Abstract Number: 1424 • ACR Convergence 2022
Cost-Effectiveness of a Progressive Spacing of Tocilizumab or Abatacept in Patients with Rheumatoid Arthritis in Sustained Remission: A Medico-Economic Analysis of the ToLEDo Trial
Joanna KEDRA¹, Lina El Houari¹, Florence Tubach¹, Benjamin granger¹ and Bruno Fautrel², ¹Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, PEPITES, F75013, Paris, France, Paris, France, ²Sorbonne University Paris, France and Pierre Louis Institute of Epidemiology and Public Health, Paris, France, Paris, France
Background/Purpose: Biologic Disease Modifying Anti-Rheumatic Drugs (bDMARDs) progressive tapering is a real opportunity in people living with rheumatoid arthritis (RA) having achieved remission both from…
Abstract Number: 1488 • ACR Convergence 2022
Incremental Healthcare Resource Utilization and Costs of Herpes Zoster in Patients with Psoriatic Arthritis: A Retrospective Cohort Study
David Singer¹, Philippe Thompson-Leduc², Siyu Ma³, Deepshekhar Gupta⁴, Wendy Cheng⁵, Selvam Sendhil⁶, Manasvi Sundar⁶, Ella Hagopian⁵, Mei Sheng Duh⁷ and Sara Poston¹, ¹GSK, Philadelphia, PA, ²Analysis Group, Inc., Montréal, QC, Canada, ³GSK/Tufts Medical Center, Boston, MA, ⁴Analysis Group, Inc., Menlo Park, CA, ⁵Analysis Group, Inc., Boston, MA, ⁶Analysis Group, Inc., Los Angeles, CA, ⁷Analysis Group Inc, Boston, MA
Background/Purpose: Patients with psoriatic arthritis (PsA) may be at increased risk of herpes zoster (HZ). HZ can involve a painful dermatomal rash and lead to…
Abstract Number: 2006 • ACR Convergence 2022
Healthcare Resource Utilization and Economic Burden of Patients with Adequate and Inadequate Responses to Advanced Therapies for Rheumatoid Arthritis in Japan
Kei Ikeda¹, Yuko Kaneko², Jayeshkumar Patel³, Toru Yamazaki⁴, Siran Fang³, Tsujita Yuki⁴ and Yutaka Kawahito⁵, ¹Chiba University Hospital, Chiba, Japan, ²Keio University School of Medicine, Tokyo, Japan, ³AbbVie, Inc., North Chicago, IL, ⁴AbbVie GK, Tokyo, Japan, ⁵Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, Kyoto, Kyoto, Japan
Background/Purpose: Substantial numbers of patients with RA receiving advanced therapies including biologics, biosimilars, and Janus kinase inhibitors do not achieve ACR50 responses and lack of…
Abstract Number: 2086 • ACR Convergence 2022
Remission and Low Disease Activity Are Associated with Lower Health Care Costs in an International Inception Cohort of Patients with Systemic Lupus Erythematosus
Ann E Clarke¹, Manuel Ugarte-Gil², Megan Barber³, John Hanly⁴, Murray Urowitz⁵, Yvan St. Pierre⁶, Caroline Gordon⁷, Sang-Cheol Bae⁸, Juanita Romero-Diaz⁹, Jorge Sanchez-Guerrero¹⁰, Sasha Bernatsky⁶, Daniel Wallace¹¹, David Isenberg¹², Anisur Rahman¹³, Joan Merrill¹⁴, Paul R Fortin¹⁵, Dafna Gladman¹⁶, Ian N. Bruce¹⁷, Michelle Petri¹⁸, Ellen M. Ginzler¹⁹, Mary Anne Dooley²⁰, Rosalind Ramsey-Goldman²¹, Susan Manzi²², Andreas Jönsen²³, Ronald van Vollenhoven²⁴, Cynthia Aranow²⁵, Meggan Mackay²⁵, Guillermo Ruiz-Irastorza²⁶, S. Sam Lim²⁷, Murat Inanc²⁸, Kenneth Kalunian²⁹, Soren Jacobsen³⁰, Christine Peschken³¹, Diane Kamen³², Anca Askanase³³, Bernardo Pons-Estel³⁴ and Graciela Alarcón³⁵, ¹University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, ²Universidad Cientifica del Sur/Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ³Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁴Division of Rheumatology, Queen Elizabeth II Health Sciences Center (Nova Scotia Rehabilitation Site) and Dalhousie University, Halifax, NS, Canada, ⁵University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada, ⁶Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁷Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ⁸Hanyang University Medical Center, Seoul, Republic of Korea, ⁹Instituto Nacional de Ciencias Medicas y Nutricion SZ, Ciudad de México, Mexico, ¹⁰Mount Sinai Hospital and University Health Network, University of Toronto, Toronto, ON, Canada, ¹¹Cedars-Sinai Medical Center, Los Angeles, CA, ¹²University College London, London, United Kingdom, ¹³Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ¹⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁵Centre ARThrite - CHU de Québec - Université Laval, Québec, QC, Canada, ¹⁶Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ¹⁷Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom, ¹⁸Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ¹⁹SUNY Downstate Health Sciences University, Department of Medicine, Brooklyn, NY, ²⁰Raleigh Neurology Associates, Chapel Hill, NC, ²¹Northwestern University Feinberg School of Medicine, Chicago, USA, Chicago, IL, ²²Allegheny Health Network, Lupus Center of Excellence, Wexford, PA, ²³Department of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Lund and Skåne University Hospital, Lund, Sweden, ²⁴Amsterdam University Medical Centers, Amsterdam, Netherlands, ²⁵Feinstein Institutes for Medical Research, Manhasset, NY, ²⁶Autoimmune Diseases Research Unit, Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, UPV/EHU, Barakaldo, Spain, ²⁷Emory University, Atlanta, GA, ²⁸Division of Rheumatology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istambul, Turkey, ²⁹University of California San Diego, La Jolla, CA, ³⁰Rigshospitalet, Copenhagen, Denmark, ³¹University of Manitoba, Winnipeg, MB, Canada, ³²Medical University of South Carolina, Charleston, SC, ³³Columbia University Medical Center, New York, NY, ³⁴Grupo Oroño - Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ³⁵The University of Alabama at Birmingham, Oakland
Background/Purpose: Remission and low disease activity (LDA) are associated with decreased flares, damage, and mortality. However, little is known about the impact of disease activity…
Abstract Number: 0881 • ACR Convergence 2021
Economic Evaluation of Neuropsychiatric (NP) Lupus in an International Inception Cohort Using a Multistate Model Approach
Ann Clarke¹, John Hanly², Yvan St.Pierre³, Caroline Gordon⁴, Sang-Cheol Bae⁵, Juanita Romero-Diaz⁶, Jorge Sanchez-Guerrero⁷, Sasha Bernatsky⁸, Daniel Wallace⁹, David Isenberg¹⁰, Anisur Rahman¹¹, Joan Merrill¹², Paul R Fortin¹³, Dafna Gladman¹⁴, Murray Urowitz¹⁵, Ian N. Bruce¹⁶, Michelle Petri¹⁷, Ellen Ginzler¹⁸, Mary Anne Dooley¹⁹, Rosalind Ramsey-Goldman²⁰, Susan Manzi²¹, Andreas Jnsen²², Graciela Alarcn²³, Ronald van Vollenhoven²⁴, Cynthia Aranow²⁵, Meggan Mackay²⁵, Guillermo Ruiz-Irastorza²⁶, S Sam Lim²⁷, Murat Inanc²⁸, Kenneth Kalunian²⁹, Soren Jacobsen³⁰, Christine Peschken³¹, Diane Kamen³², Anca Askanase³³ and Vernon Farewell³⁴, ¹University of Calgary, Calgary, AB, Canada, ²Dalhousie University, Halifax, NS, Canada, ³Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁴Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁵Hanyang University Medical Center, Seoul, Republic of Korea, ⁶Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Federal District, Mexico, ⁷Instituto Nacional de Ciencias Médicas y Nutrición, Inmunología y Reumatología, Mexico City, Mexico, ⁸McGill University, Montréal, QC, Canada, ⁹Cedars-Sinai, Los Angeles, CA, ¹⁰Centre for Rheumatology, University College London, London, United Kingdom, ¹¹University College London, London, United Kingdom, ¹²Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹³CHU de Quebec - Universite Laval, Québec City, QC, Canada, ¹⁴Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ¹⁵Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada, ¹⁶University of Manchester, Manchester, United Kingdom, ¹⁷Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁸SUNY Downstate Health Sciences University, Brooklyn, NY, ¹⁹Raleigh Neurology Associates, Chapel Hill, NC, ²⁰Northwestern University, Chicago, IL, ²¹Allegheny Health Network, Wexford, PA, ²²Lund University, Lund, Sweden, ²³University of Alabama at Birmingham, Birmingham, AL, ²⁴Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ²⁵Feinstein Institutes for Medical Research, Manhasset, NY, ²⁶Hospital Universitario Cruces, University of the Basque Country, Bizkaia, Spain, ²⁷Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ²⁸Istanbul University Faculty of Medicine, Istanbul, Turkey, ²⁹UC San Diego, La Jolla, CA, ³⁰Rigshospitalet, Copenhagen, Denmark, ³¹University of Manitoba, Winnipeg, MB, Canada, ³²Medical University of South Carolina, Charleston, SC, ³³Columbia University Medical Center, New York, NY, ³⁴University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Little is known about the economic burden of NP lupus. We estimated annual and cumulative direct and indirect costs (DC, IC) associated with NP…
Abstract Number: 0981 • ACR Convergence 2021
Clinical and Economic Burden of Herpes Zoster in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study Using Administrative Claims
David Singer¹, Philippe Thompson-Leduc², Sara Poston¹, Deepshekhar Gupta³, Wendy Cheng⁴, Siyu Ma¹, Francesca Devine⁵, Alexandra Enrique³, Mei Sheng Duh⁶ and Jeffrey Curtis⁷, ¹GlaxoSmithKline, Philadelphia, PA, ²Analysis Group, Inc., Montréal, QC, Canada, ³Analysis Group, Inc., Menlo Park, CA, ⁴Analysis Group, Inc., Boston, MA, ⁵Analysis Group, Inc., New York, NY, ⁶Analysis Group, Boston, MA, ⁷Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL

Background/Purpose: Herpes zoster (HZ) is a disease caused by the reactivation of the varicella-zoster virus in previously infected individuals and is characterized by a painful…
Abstract Number: 1076 • ACR Convergence 2021
Combining Fuzzy Logic with Time-Driven Activity Based Costing Within the Rheumatoid Arthritis Care Cycle: Insights from a Dutch Hospital
Fiona Koster¹, Deirisa Lopes Barreto², Marc Kok³ and Angelique Weel-Koenders¹, ¹Maasstad Hospital Rotterdam, Rotterdam, Netherlands, ²Maasstad Hospital Rotterdam, Rotterdam, ³Maasstad Hospital, Rotterdam, Netherlands
Background/Purpose: Transparency and management of healthcare costs is warranted for rheumatoid arthritis (RA) as the disease places a great economic burden on a patient and…
Abstract Number: 1118 • ACR Convergence 2021
The Association of Hand OA with Paid an Unpaid Work Impairment and Related Costs: The Hand Osteoarthritis in Secondary Care Cohort
Sietse Terpstra¹, Lotte van de Stadt¹, Annelies Boonen², Frits Rosendaal¹ and Margreet Kloppenburg¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre+ (MUMC+), Maastricht, Limburg, Netherlands
Background/Purpose: Rheumatic musculoskeletal diseases (RMDs) can cause impairment at paid and unpaid work and contributes to societal burden and costs. However, data on this topic…
Abstract Number: 1852 • ACR Convergence 2021
Healthcare Utilization and Economic Burden in Systemic Sclerosis
Leonardo Martin Calderon¹, Mitali Chaudhary¹ and Janet Pope², ¹Western University, London, ON, Canada, ²University of Western Ontario, London, ON, Canada
Background/Purpose: Systemic Sclerosis (SSc) is a multi-system autoimmune disease, characterized by vasculopathy, fibrosis of the skin and internal organs, and autoimmunity with distinct antibodies. SSc…
Abstract Number: 0143 • ACR Convergence 2021
Economic and Healthcare Resource Use Burden of Systemic Sclerosis
Dinesh Khanna¹, Dan Furst², Justin Li³, Qian Meng⁴, Tamara Lesperance⁵, Kenyatta Peoples⁶, Farah Ali⁵, Brian LaMoreaux⁵ and Stephanie Taylor⁷, ¹University of Michigan, Ann Arbor, MI, ²University of California Los Angeles, Los Angeles, CA, ³Trinity Partners, Waltham, MA, ⁴Trinity Life Sciences, Waltham, MA, ⁵Horizon Therapeutics plc, Deerfield, IL, ⁶Horizon Therapeutics plc, Lake Forest, IL, ⁷Horizon Therapeutics plc, Whitehouse Station, NJ
Background/Purpose: The clinical burden of systemic sclerosis (SSc) is substantial and typically characterized by progressive skin, gastrointestinal, pulmonary, and cardiovascular complications and premature death. The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].